{"id":"NCT00249873","sponsor":"Sanofi","briefTitle":"Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)","officialTitle":"A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-06","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2005-11-07","resultsPosted":"2010-03-26","lastUpdate":"2015-06-15"},"enrollment":7554,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Atrial Fibrillation","Vascular Risk"],"interventions":[{"type":"DRUG","name":"clopidogrel (SR25990C)","otherNames":["PlavixÂ®"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Clopidogrel + ASA","type":"EXPERIMENTAL"},{"label":"Placebo + ASA","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if the combination of clopidogrel 75mg once daily (od) plus aspirin 100mg daily (recommended dose) is better than aspirin alone (100mg daily recommended dose) for preventing vascular events such as stroke and heart attack during approximately three years of follow-up in patients with atrial fibrillation associated with at least one major risk factor of vascular event such as elderly, blood pressure increase, history of stroke or transient ischemic attack or left ventricular dysfunction etc. The study will also accept patients with atrial fibrillation and unwilling to take oral anticoagulant therapy.","primaryOutcome":{"measure":"First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication","timeFrame":"expected median follow-up of approximately 3 years","effectByArm":[{"arm":"Clopidogrel + ASA","deltaMin":832,"sd":null},{"arm":"Placebo + ASA","deltaMin":924,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0133"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":12},"locations":{"siteCount":30,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Czechia","Denmark","Finland","France","Germany","Greece","Hong Kong","Hungary","Italy","Malaysia","Mexico","Netherlands","Norway","Poland","Portugal","Singapore","South Africa","Spain","Sweden","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["19336502","20979470"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1154,"n":3772},"commonTop":["Any Infections and infestations","Any Gastrointestinal disorders","Any Nervous system disorders","Any Musculoskeletal and connective tissue disorders","Any General disorders and administration site conditions"]}}